On August 18, 2026, Haemonetics Corp HAE shares rose 15.9%, bringing the current price to $104.65. This performance reflects a significant 52-week range, with a low of $47.32 and a high of $106.67, highlighting the stock's volatility and recent upward momentum.
- GF Valueâ„¢ verdict: Current price of $104.65 is 22.8% above the GF Valueâ„¢ of $85.22.
- GF Scoreâ„¢ is 85/100, indicating a strong overall rating.
- Notable signal: Insiders have bought $0.1M in stock over the past 12 months, with no selling activity.
Is HAE Overvalued or Undervalued?
According to the GF Valueâ„¢, Haemonetics Corp is currently overvalued, with its market price of $104.65 exceeding the fair value estimate of $85.22 by 22.8%. This overvaluation suggests a lack of margin of safety for potential investors, indicating that the stock may be trading at a premium in relation to its intrinsic value. GF Valueâ„¢ is GuruFocus' proprietary intrinsic-value estimate, which is derived from various factors including historical trading multiples, past business growth, and future performance projections. Given this context, the GF Valuation label identifies HAE as modestly overvalued, which poses a risk for investors looking for solid entry points.
The risk associated with investing in an overvalued stock like HAE includes the potential for price corrections if market sentiment shifts or if the company fails to meet growth expectations. Therefore, while the company's performance over the past year shows significant growth—up 97%—the elevated price level raises concerns about sustainability.
How Does HAE's Valuation Compare to Its History?
| Metric | Current | Historical |
|---|---|---|
| P/E (TTM) | 51.3x | 35.8x |
| Forward P/E | 19.8x | N/A |
Haemonetics Corp's current P/E ratio of 51.3x is significantly higher than its 5-year median P/E of 35.8x, suggesting that the stock is trading at a higher valuation compared to its historical levels. The forward P/E of 19.8x indicates that analysts expect a decline in valuation multiples in the future, which aligns with the GF Valueâ„¢ verdict of being overvalued. This P/E analysis reinforces concerns about HAE's current pricing versus historical standards.
What Does HAE's GF Scoreâ„¢ Tell Us?
The GF Scoreâ„¢ measures a company's financial strength, profitability, growth potential, valuation, and momentum to provide an overall rating. Haemonetics Corp has a GF Scoreâ„¢ of 85/100, which signifies strong performance in several key areas, particularly in profitability and growth. The strongest sub-ranks are in Profitability and Growth, each rated 8/10, indicating that the company has been effective in generating profits and is expected to continue growing. However, the Financial Strength rank of 5/10 suggests that there may be some areas for improvement in its balance sheet.
| Metric | Rating |
|---|---|
| GF Scoreâ„¢ | 85 |
| Financial Strength | 5/10 |
| Profitability | 8/10 |
| Growth | 8/10 |
| Valuation | 7/10 |
| Momentum | 6/10 |
The overall scores indicate that while HAE demonstrates strong profitability and growth potential, its financial strength may be a concern, particularly given the stock's current valuation levels. The valuation rank of 7/10 suggests that there is room for caution as well, especially when considering the GF Valueâ„¢ assessment of overvaluation.
What Are Gurus and Insiders Doing with HAE?
Currently, seven gurus hold positions in Haemonetics Corp, with five of them having added to their stakes and two trimming their holdings in recent quarters. This indicates a generally positive sentiment among institutional investors, which can be a reassuring factor for potential investors. Insider activity also supports this sentiment, as insiders have purchased $0.1M worth of shares over the past year without any selling activity, suggesting confidence in the company's future prospects.
This pattern of buying among insiders and the majority of gurus indicates a level of commitment to the company, which can be interpreted as a positive signal. However, the fact that some gurus have reduced their positions may also warrant attention, as it could reflect differing views on the stock's valuation or future performance.
What This Means for Investors
In conclusion, based on the GF Valueâ„¢, Haemonetics Corp appears to be overvalued at its current price of $104.65, given the fair value estimate of $85.22. This situation presents a risk for investors in terms of potential price corrections if the stock does not meet growth expectations. While the strong GF Scoreâ„¢ indicates solid fundamentals and insider confidence, the overvaluation raises caution regarding entry points. For more detailed insights, visit the Haemonetics Corp HAE stock page for comprehensive analysis.
Frequently Asked Questions
What is HAE's GF Scoreâ„¢?
HAE's GF Scoreâ„¢ is 85/100, which indicates strong performance across various metrics, particularly in profitability and growth.
Is HAE overvalued or undervalued?
HAE is currently overvalued, with a market price that is 22.8% higher than the GF Valueâ„¢ estimate.
What is HAE's P/E ratio?
HAE has a P/E (TTM) of 51.3x, which is significantly above its 5-year median P/E of 35.8x, indicating a higher valuation compared to its historical levels.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
